We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
+0.84%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$1.64B
AUM Growth
+$261M
Cap. Flow
+$274M
Cap. Flow %
16.76%
Top 10 Hldgs %
92.42%
Holding
31
New
5
Increased
12
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
LLYVK icon
Liberty Live Group Series C
LLYVK
+$51.7M
2
RNAM
Avidity Biosciences
RNAM
+$16.4M
3
XNCR icon
Xencor
XNCR
+$15.2M
4
EYPT icon
EyePoint Inc
EYPT
+$3.76M
5
PRTA icon
Prothena Corp
PRTA
+$3.53M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$24.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.9M
3
QXO
QXO Inc
QXO
+$12.9M
4
RVMD icon
Revolution Medicines
RVMD
+$1.1M
5
ARGX icon
argenx
ARGX
+$879K

Sector Composition

Rank Sector Weight
1 Industrials 24.21%
2 Healthcare 16.12%
3 Communication Services 12.58%
4 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$442M 27.02%
755,000
+200,000
+36% +$118M
QXO
2
QXO Inc
QXO
$14.9B
$396M 24.21%
24,933,825
-816,956
-3% -$12.9M
IWM icon
3
PUT
iShares Russell 2000 ETF
IWM
$82.2B
$328M 20.04%
1,485,000
+420,000
+39% +$95.8M
LBRDK icon
4
Liberty Broadband Class C
LBRDK
$4.43B
$151M 9.2%
2,015,710
+21,200
+1% +$1.77M
LLYVK icon
5
Liberty Live Group Series C
LLYVK
$9.45B
$55.3M 3.38%
+812,792
New +$51.7M
ARGX icon
6
argenx
ARGX
$53.8B
$32.6M 1.99%
52,928
-1,500
-3% -$879K
RVMD icon
7
Revolution Medicines
RVMD
$39.6B
$31.1M 1.9%
710,260
-21,700
-3% -$1.1M
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
$27.1M 1.65%
748,752
+97,900
+15% +$3.42M
ASND icon
9
Ascendis Pharma A/S
ASND
$17.1B
$25.5M 1.55%
184,872
-5,200
-3% -$684K
MLTX icon
10
MoonLake Immunotherapeutics
MLTX
$1.64B
$24.3M 1.48%
447,935
+59,100
+15% +$3.02M
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.82B
$19.7M 1.2%
161,935
+28,400
+21% +$3.48M
LKFT
12
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$18.6M 1.13%
674,762
+117,000
+21% +$3.26M
XNCR icon
13
Xencor
XNCR
$1.3B
$15.2M 0.93%
+660,000
New +$15.2M
CYTK icon
14
Cytokinetics
CYTK
$10.9B
$15M 0.91%
318,448
+61,999
+24% +$3.22M
ARVN icon
15
Arvinas
ARVN
$517M
$13.7M 0.84%
713,778
+139,400
+24% +$3.39M
RNAM
16
DELISTED
Avidity Biosciences
RNAM
$11.4M 0.69%
+391,300
New +$16.4M
PRTA icon
17
Prothena Corp
PRTA
$453M
$9.1M 0.56%
657,071
+223,600
+52% +$3.53M
RLAY icon
18
Relay Therapeutics
RLAY
$4.34B
$8.96M 0.55%
2,175,646
+549,500
+34% +$2.99M
EYPT icon
19
EyePoint Inc
EYPT
$1.12B
$8.28M 0.51%
1,111,104
+403,700
+57% +$3.76M
SLDB icon
20
Solid Biosciences
SLDB
$858M
$3.85M 0.23%
961,251
– –
ANNA
21
AleAnna Inc
ANNA
$141M
$197K 0.01%
+27,717
New +$201K
ANNAW
22
AleAnna Inc Warrant
ANNAW
$12.5M
$68.6K ﹤0.01%
+490,000
New +$74.7K
MNYWW
23
MoneyHero Ltd Warrants
MNYWW
$49.4K ﹤0.01%
895,000
– –
LSBPW
24
DELISTED
LakeShore Biopharma Warrants
LSBPW
$48.5K ﹤0.01%
489,999
– –
GATEW
25
DELISTED
Marblegate Acquisition Corp. Warrant
GATEW
$25.7K ﹤0.01%
735,000
– –
1
2

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Finepoint Capital held 31 positions worth $1.64B, up 19% from $1.38B the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Finepoint Capital deployed $274M of net new capital in Q4 2024, opening 5 new positions and adding to 12 existing holdings. Its largest new stake was Liberty Live Group Series C: 812,792 shares worth $55.3M.

By sector, the portfolio is most concentrated in Industrials at 24% of assets, down from 30% a quarter earlier, followed by Healthcare and Communication Services.

On the sell side, the largest reduction was QXO Inc, an estimated $12.9M trimmed.

  • Finepoint Capital's largest Q4 2024 buy was Liberty Live Group Series C: 812,792 shares worth $55.3M.
  • Finepoint Capital added most to EyePoint Inc in Q4 2024, an estimated $3.76M increase.
  • Finepoint Capital's biggest Q4 2024 reduction was QXO Inc, cutting an estimated $12.9M.
  • Finepoint Capital fully exited Travere Therapeutics in Q4 2024, selling an estimated $24.9M.
  • Finepoint Capital's ten largest holdings make up 92% of its $1.64B portfolio in Q4 2024.
  • Finepoint Capital opened 5 new positions and closed 5 in Q4 2024.
  • Finepoint Capital's portfolio value rose 19% quarter-over-quarter to $1.64B.

Based on Finepoint Capital's 13F filing for Q4 2024, filed 13 Feb 2025.